Publication
sFlt-1/PlGF Ratio for the Predictive Diagnosis of Preeclampsia: Budget Impact Analysis from the Public Healthcare Perspective in Portugal
| dc.contributor.author | Campos, A | |
| dc.contributor.author | Machado, AP | |
| dc.contributor.author | Martins, H | |
| dc.contributor.author | José Pais, MS | |
| dc.contributor.author | Érsek, K | |
| dc.contributor.author | Lopes, N | |
| dc.date.accessioned | 2022-07-28T14:12:42Z | |
| dc.date.available | 2022-07-28T14:12:42Z | |
| dc.date.issued | 2019 | |
| dc.description.abstract | Overview and Aims: The last decade brought relevant insights into the pathophysiology of preeclampsia (PE), namely the role of the circulating levels of placental growth factor (PlGF) and soluble Fms-like tyrosine kinase-1 (sFlt-1). The purpose of this study is to estimate the financial impact of introducing the sFlt-1/PlGF ratio for the evaluation of women with suspicion of PE in the Portuguese National Healthcare System (SNS). Study Design: budget impact study evaluating short-term costs associated with the introduction of the sFlt-1/PlGF ratio from the SNS payer’s perspective. The time horizon for the study is 1 year. Population: The target population consists of women presenting to the healthcare system with signs or symptoms su ggestive of preeclampsia (estimated in 8500 subjects). Methods: A decision-tree model was used to estimate the budget impact of the introduction of the sFlt-1/PlGF ratio in the SNS. The model compares the management costs in the current clinical practice (“no test” scenario) vs. current diagnostic procedures plus the sFlt-1/PlGF ratio (“test” scenario). Clinical inputs have been derived primarily from literature review and, where data was unavailable, expert opinion. Resources and unit costs have been obtained from Portugal-specific sources. Results: In the current standard practice (no test), total costs were estimated to be €9 863 264 (€1160 per patient), with unnecessary admissions representing about €3,5 million. Total costs in the test scenario sum up to €9 781 194 (€1150 per patient), representing a cost saving to the system of €82 070 (€10 per patient), mainly due to a reduction of false positives and related unnecessary hospitalizations of women not developing PE. Conclusions: There is favorable economic evidence about the introduction of the sFlt- 1/PlGF ratio in the SNS. The generated savings appear to offset the costs related to the test. | pt_PT |
| dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
| dc.identifier.citation | Acta Obstet Ginecol Port 2019;13(2):82-90 | pt_PT |
| dc.identifier.uri | http://hdl.handle.net/10400.17/4165 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.publisher | Federação das Sociedades Portuguesas de Obstetrícia e Ginecologia | pt_PT |
| dc.subject | Preeclampsia | pt_PT |
| dc.subject | Pregnancy | pt_PT |
| dc.subject | Biomarkers | pt_PT |
| dc.subject | Costs and Cost Analysis | pt_PT |
| dc.subject | MAC OBS | pt_PT |
| dc.title | sFlt-1/PlGF Ratio for the Predictive Diagnosis of Preeclampsia: Budget Impact Analysis from the Public Healthcare Perspective in Portugal | pt_PT |
| dc.title.alternative | sFlt-1/PIGF no Diagnóstico Preditivo de Pré-eclâmpsia: Estudo de Impacto Económico em Portugal | pt_PT |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 90 | pt_PT |
| oaire.citation.issue | 2 | pt_PT |
| oaire.citation.startPage | 82 | pt_PT |
| oaire.citation.volume | 13 | pt_PT |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | article | pt_PT |